Source Newsroom: Tufts University
Newswise — Breast cancer stem cells (CSCs), the aggressive cells thought to be resistant to current anti-cancer therapies and which promote metastasis, are stimulated by estrogen via a pathway that mirrors normal stem cell development. Disrupting the pathway, researchers were able to halt the expansion of breast CSCs, a finding that suggests a new drug therapy target. The study, done in mice, is published in the Proceedings of the National Academy of Sciences (PNAS) Early Edition this week.
“A critical aspect of our work was to discover that estrogen could promote breast cancer growth by modulating the proportion of breast CSCs. Since CSCs were not directly sensitive to estrogen, it wasn’t clear how estrogen could affect their numbers. However, we found that hormone-sensitive cancer cells can communicate with CSCs to regulate their numbers. By disrupting the interaction between cancer cell populations we were able to prevent tumor growth,” said Charlotte Kuperwasser, PhD, associate professor in the anatomy and cellular biology and radiation oncology departments at Tufts University School of Medicine, and member of the genetics and cell, molecular & developmental biology program faculties at the Sackler School of Graduate Biomedical Sciences at Tufts.
“Interestingly, this signaling pathway involves many of the same players that control normal stem cell biology, raising a more general possibility that CSCs in other tumors might be regulated by the mechanisms guiding normal development,” said Kuperwasser.
Kuperwasser and colleagues from MIT and Harvard used a mouse model to examine the behavior of cancerous human breast tissue with a method that mimics the human body more closely than standard mouse models. The researchers first examined estrogen’s effect on breast CSC growth, finding that estrogen caused breast CSC numbers to increase by nearly 800 percent. Since few breast CSCs contain estrogen receptors, the researchers suspected that estrogen’s actions were through a signaling mechanism from nearby cells that express the receptors.
“When nearby cells were exposed to estrogen, they secreted 14 times more FGF9, a signaling protein that drives CSC proliferation. When we blocked the FGF pathway with a small molecule inhibitor, we saw loss of CSC growth, tumorspheres generation, and even tumor formation. We then linked FGF signaling to the Tbx3 signaling axis, which is also important for embryonic mammary gland development,” said first author Christine Fillmore, PhD, a 2009 graduate of the genetics program at the Sackler School and currently a research fellow in genetics at Children’s Hospital Boston.
“These results show that interfering with this signaling pathway is a promising strategy for targeting breast CSCs. We are hopeful that the improved understanding of the mechanisms that promote breast CSCs will lead to the development of drugs that can be used to halt CSC proliferation,” said Kuperwasser.
Kuperwasser also leads a laboratory at the Molecular Oncology Research Institute (MORI) at Tufts Medical Center, which is dedicated to the exploration of the molecular mechanisms of cancer and the translation of findings into the clinic.
Additional authors on the study include Piyush Gupta, PhD, formerly of the Broad Institute, and now a member of the Whitehead Institute for Biomedical Research as well as an assistant professor of biology at MIT; Jenny Rudnick, a graduate student in the cell, molecular & developmental biology program at the Sackler School and member of the Kuperwasser lab at MORI; Silvia Caballero, formerly a participant in the Post-baccalaureate Research Education Program at the Sackler School, and now at Cornell University; Patricia Keller, PhD, a postdoctoral fellow in the department of anatomy and cellular biology at TUSM and member of Kuperwasser’s lab at MORI; and Eric Lander, PhD, founding director of the Broad Institute, professor of biology at MIT, and professor of systems biology at Harvard Medical School.
This study was supported by the Breast Cancer Research Foundation, the Raymond and Beverly Sackler Foundation, and by the National Cancer Institute, part of the National Institutes of Health; and by a Broadway on Beachside Postdoctoral Fellowship from the New England Division of the American Cancer Society to Patricia Keller.
The Post-baccalaureate Research Education Program at the Sackler School is funded through the Division of Minority Opportunities in Research program of the National Institute of General Medical Sciences, an institute of the National Institutes of Health, and by the Sackler School.
Fillmore CM, Gupta PB, Rudnick JA, Caballero S, Keller PJ, Lander ES, and Kuperwasser C. PNAS Early Edition. “Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling.” Published online November 22, 2010, doi:10.1073/pnas.1007863107
About Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences
Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts University are international leaders in innovative medical education and advanced research. The School of Medicine and the Sackler School are renowned for excellence in education in general medicine, biomedical sciences, special combined degree programs in business, health management, public health, bioengineering and international relations, as well as basic and clinical research at the cellular and molecular level. Ranked among the top in the nation, the School of Medicine is affiliated with six major teaching hospitals and more than 30 health care facilities. Tufts University School of Medicine and the Sackler School undertake research that is consistently rated among the highest in the nation for its effect on the advancement of medical science.
If you are a member of the media interested in learning more about this topic, or speaking with a faculty member at the Tufts University School of Medicine, the Sackler School of Graduate Biomedical Sciences, or another Tufts health sciences researcher, please contact Siobhan Gallagher at 617-636-6586.